Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00442364 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt
A Phase 2 study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00442364 is a Phase 2 study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 60 participants.
The verdict
NCT00442364, a Phase 2 study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of the Varisolve® procedure in patients with right-to-left cardiac shunt (a defect in the heart).
Interventions
- DRUG Polidocanol (1%) Microfoam (Varisolve)
- PROCEDURE Endovenous Microfoam Occlusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2007-03 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00442364
The ClinicalTrials.gov registry entry for NCT00442364 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Polidocanol (1%) Microfoam (Varisolve) is the first listed.
NCT00442364 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00442364 about?
NCT00442364 is a clinical study titled "Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt". The purpose of this study is to determine the safety of the Varisolve® procedure in patients with right-to-left cardiac shunt (a defect in the heart).
What is the current status of trial NCT00442364?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2007-03. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00442364?
The interventions under investigation include: Polidocanol (1%) Microfoam (Varisolve) (DRUG), Endovenous Microfoam Occlusion (PROCEDURE).
Who is sponsoring clinical trial NCT00442364?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.